CR20120192A - Nueva asociación entre la 4{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen - Google Patents

Nueva asociación entre la 4{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen

Info

Publication number
CR20120192A
CR20120192A CR20120192A CR20120192A CR20120192A CR 20120192 A CR20120192 A CR 20120192A CR 20120192 A CR20120192 A CR 20120192A CR 20120192 A CR20120192 A CR 20120192A CR 20120192 A CR20120192 A CR 20120192A
Authority
CR
Costa Rica
Prior art keywords
hexahydrociclopenta
acetilcolinesterase
propoxi
pirrol
inhibitor
Prior art date
Application number
CR20120192A
Other languages
English (en)
Inventor
Caryn Trocme-Thibierge
Aurore Sors
Florence Keime-Guibert
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44351420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120192(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CR20120192A publication Critical patent/CR20120192A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Nueva asociación entre la 4-(3-(HEXAHIDROCICLOPENTA)C PIRROL-2(IH)-IL) PROPOXI)BENZAMIDA Y UN INHIBIDOR DE LA ACETILCOLINESTERASA.
CR20120192A 2011-05-02 2012-04-19 Nueva asociación entre la 4{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen CR20120192A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1101347A FR2974729B1 (fr) 2011-05-02 2011-05-02 Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
CR20120192A true CR20120192A (es) 2012-12-06

Family

ID=44351420

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120192A CR20120192A (es) 2011-05-02 2012-04-19 Nueva asociación entre la 4{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen

Country Status (29)

Country Link
US (3) US8940785B2 (es)
EP (1) EP2520296A1 (es)
JP (1) JP2012232978A (es)
KR (2) KR101493757B1 (es)
CN (1) CN102764439A (es)
AP (1) AP3104A (es)
AR (1) AR086146A1 (es)
BR (1) BR102012010244A2 (es)
CA (1) CA2775624A1 (es)
CL (1) CL2012001102A1 (es)
CR (1) CR20120192A (es)
CU (1) CU20120064A7 (es)
EA (1) EA020987B1 (es)
EC (1) ECSP12011862A (es)
FR (1) FR2974729B1 (es)
GE (1) GEP20146076B (es)
MA (1) MA34776B1 (es)
MX (1) MX2012005103A (es)
NI (1) NI201200070A (es)
PE (1) PE20130016A1 (es)
PH (1) PH12012000088A1 (es)
RU (1) RU2013153140A (es)
SG (2) SG2014010904A (es)
SV (1) SV2012004203A (es)
TN (1) TN2012000177A1 (es)
TW (1) TW201247200A (es)
UY (1) UY34050A (es)
WO (1) WO2012150412A1 (es)
ZA (1) ZA201203163B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2976285B1 (fr) * 2011-06-08 2013-05-24 Servier Lab Procede de synthese et forme cristalline du chlorhydrate de 4-{3-[cis-hexahydrocypenta[c]pyrrol-2(1h)-yl]propoxy}benzamide ainsi que les compositions pharmaceutiques qui la contiennent
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
AU2017313427B2 (en) 2016-08-18 2020-01-30 Suven Life Sciences Limited Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors
MX377517B (es) * 2016-08-18 2025-03-10 Suven Life Sciences Ltd Combinacion triple de agonistas inversos del receptor de histamina 3, inhibidores de acetilcolinestearasa y antagonistas del receptor nmda.
CN108371660B (zh) * 2017-12-14 2020-03-10 五邑大学 一种四氢环戊二烯并吡咯化合物及其衍生物的用途
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
EP3973586A4 (en) * 2019-05-21 2023-01-11 La Pharma Tech Inc. NEW PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL, BEHAVIORAL AND COGNITIVE DISORDERS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RU2384571C2 (ru) * 2004-04-28 2010-03-20 Такеда Фармасьютикал Компани Лимитед Конденсированное хинолиновое производное и его применение
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
TW200845977A (en) * 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
CL2008002998A1 (es) * 2007-10-10 2009-11-20 Takeda Pharmaceuticals Co Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion.
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
FR2937251B1 (fr) * 2008-10-16 2011-03-18 Servier Lab Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil
FR2953515B1 (fr) * 2009-12-09 2011-12-23 Servier Lab Nouveaux derives du type hexahydrocyclopenta[b]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
EA020987B1 (ru) 2015-03-31
CA2775624A1 (fr) 2012-11-02
UY34050A (es) 2012-11-30
FR2974729A1 (fr) 2012-11-09
NZ599633A (en) 2014-02-28
AP2012006232A0 (en) 2012-04-30
AP3104A (en) 2015-01-31
CU20120064A7 (es) 2013-12-27
JP2012232978A (ja) 2012-11-29
ECSP12011862A (es) 2012-07-31
CL2012001102A1 (es) 2014-06-20
TW201247200A (en) 2012-12-01
GEP20146076B (en) 2014-04-10
ZA201203163B (en) 2013-01-30
EP2520296A1 (fr) 2012-11-07
US20150080379A1 (en) 2015-03-19
SG185240A1 (en) 2012-11-29
PH12012000088A1 (en) 2023-12-18
RU2013153140A (ru) 2015-06-10
US20150080378A1 (en) 2015-03-19
US8940785B2 (en) 2015-01-27
SV2012004203A (es) 2012-08-23
MX2012005103A (es) 2013-06-05
KR20130130238A (ko) 2013-12-02
KR20140051200A (ko) 2014-04-30
BR102012010244A2 (pt) 2013-06-18
TN2012000177A1 (fr) 2013-12-12
US20120283244A1 (en) 2012-11-08
MA34776B1 (fr) 2014-01-02
KR101493757B1 (ko) 2015-02-16
EA201200527A1 (ru) 2012-12-28
PE20130016A1 (es) 2013-01-26
NI201200070A (es) 2012-11-09
FR2974729B1 (fr) 2013-04-19
AR086146A1 (es) 2013-11-20
WO2012150412A1 (fr) 2012-11-08
SG2014010904A (en) 2014-05-29
CN102764439A (zh) 2012-11-07

Similar Documents

Publication Publication Date Title
UY34161A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida, sus usos, y composiciones que la contienen
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
UY34800A (es) Combinaciones farmacéuticas que contienen un inhibidor de 11-beta-hidroxiesteroide dehidrogenasa-1 útil en trastornos metabólicos
UA122520C2 (uk) Кристалічна форма 2-[4-(4-хлорфенокси)-2-(трифторметил)феніл]-1-(1,2,4-триазол-1-іл)пропан-2-олу, агрохімічна композиція, застосування та спосіб боротьби зі шкідливими грибами
MX394473B (es) Composiciones farmaceuticas que comprenden glitazonas y activadores de nrf2.
DOP2013000063A (es) Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación
PE20150617A1 (es) Formas solidas de 3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona o un estereoisomero del mismo, de sus sales, y composiciones que comprenden las mismas
EA201790715A1 (ru) Новые соединения
IL235761A0 (en) Process for preparing n - [5 - (3, 5 - difluoro - benzyl) -1h - indazole - 3 - yl] - 4 - (4 - methyl - piperazine - 1 - yl) - 2 - (tetrahydro - pyran - 4 - ylamino ) – benzamide
CR20140494A (es) Inhibidores de dgat1 de eter ciclico de cabeza de puente
MX2017000134A (es) Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3 ,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carb oxamida.
CU20140060A7 (es) 4-{4-[({[ 4- cloro-3-( trifluorometil) fenil] amino} carbonil) amino]-3- fluorofenoxi}-n-metilpiridina-2- carboxamida y su monohidrato
UY33930A (es) Inhibidores novedosos de quinasas
UA110642C2 (uk) Композиція гербіциду і сафенеру
PL3207928T3 (pl) Preparat złożony, zawierający nową pochodną kwasu 3-(4-(benzyloksy)fenylo)heks-4-ynowego oraz inny składnik czynny, przeznaczony do zapobiegania lub leczenia chorób metabolicznych
SV2012004203A (es) Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen
CL2016001172A1 (es) Nuevos inhibidores de dgat2.
UY34722A (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil] etil}amino)-1-hidroxietil]-8- hidroxiquinolin-2(1h)-ona
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
ZA202003028B (en) Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
SV2011003857A (es) Sales n-[6-(cis-2,6-dimetil-morfolin-4-il)- piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.
NI201200178A (es) Nueva asociación entre la 4 - { 3 -[ cis - hexahidrociclopenta [c] pirrol - 2 (1h) - il ] propoxi } benzamida y un antagonista de los receptores nmda y las composiciones farmacéuticas que la contienen
MX2016001391A (es) Compuestos de urea y su uso como inhibidores de la enzima amida hidrolasa de acido graso (faah).
EP2814494A4 (en) USE OF SMALL MOLECULAR INHIBITORS FOR AIMING INTERACTION BETWEEN RAC-GTPASE AND P67 (PHOX)
MX2016000797A (es) Imidazolcarboxamidas y su uso como inhibidores de amida de acidos grasos hidrolasa (faah).